Phase 2 Trial

Adverum Biotechnologies Inc (NASDAQ: ADVM) plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 10^11 vg/eye dose and a new lower 6 X 10^10 vg/eye dose, with three new enhanced steroid prophylaxis regimens in wet age-related macular degeneration (wet AMD).  The...

CytomX Therapeutics Inc (NASDAQ: CTMX) announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC). The CD71-directed conditionally activated antibody-drug conjugate (ADC...

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson experienced a Complete Response (CR). Under treatment with Namodenoson, the patient has now survived five years....

Bellerophon Therapeutics Inc (NASDAQ: BLPH) shares are trading higher after topline data from Phase 2 study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse via right heart catheterization for pulmonary hypertension associated with sarcoidosis (PH-Sarc)....

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington's disease.  AMT-130 was generally well tolerated at the lower dose of 6x1012 vector genomes (vg). There have...

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-19. ARCT-154 and ARCT-165 are being studied in a Phase 1/2 trial in U.S. and Singapore...

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial includes patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have...

Axcella Therapeutics Inc (NASDAQ: AXLA) has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long COVID. Phase 2a evaluates the efficacy and safety of AXA1125 in patients with exertional fatigue related to Long COVID....

Seres Therapeutics Inc (NASDAQ: MCRB) announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate ulcerative colitis (UC).  In July, the Company posted the topline data readout, which noted that the SER-287 Phase...

Vaxart Inc (NASDAQ: VXRT) plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant in two different studies expected to begin next month. Vaxart will test its COVID-19 oral vaccine candidate against omicron in the first...

GeoVax Labs Inc (NASDAQ: GOVX) initiated vaccine dosing in the Phase 2 portion of its Phase 1/2 trial of COH04S1 COVID-19 vaccine to target both the spike (S) and nucleocapsid (N) proteins. The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy...

Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape with the anticipated availability of new antiviral treatment regimens. In addition to MORNINGSKY, the follow-on...

Pfizer Inc (NYSE: PFE) announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR trial of Paxlovid.  These results were consistent with the interim analysis, showing Paxlovid reduced the risk of hospitalization or death for any cause by...

Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in patients relapsed or refractory acute myeloid leukemia (AML) who had received at least one prior line of therapy. Data were presented at the American Society of Hematology (ASH)...

Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients.  The Company shared the data at the American Society of Hematology (ASH) Annual Meeting & Exposition. In updated results from the...